CN102724962B - 包衣药物球状体及其用于消除或减少病症比如呕吐和腹泻的用途 - Google Patents

包衣药物球状体及其用于消除或减少病症比如呕吐和腹泻的用途 Download PDF

Info

Publication number
CN102724962B
CN102724962B CN201080060547.0A CN201080060547A CN102724962B CN 102724962 B CN102724962 B CN 102724962B CN 201080060547 A CN201080060547 A CN 201080060547A CN 102724962 B CN102724962 B CN 102724962B
Authority
CN
China
Prior art keywords
weight
neratinib
formulations
maleate
neratinib maleate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080060547.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN102724962A (zh
Inventor
斯里帕亚·文卡塔·拉马纳·拉奥
赛义德·穆扎法·沙
克里斯多佛·理查德·迪奥里奥
玛加·文茨尔-约恩契奇
尤金·墨菲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Priority to CN201710247663.7A priority Critical patent/CN107441058A/zh
Priority to CN201610509189.6A priority patent/CN106074445B/zh
Priority to CN201710247590.1A priority patent/CN107308130B/zh
Publication of CN102724962A publication Critical patent/CN102724962A/zh
Application granted granted Critical
Publication of CN102724962B publication Critical patent/CN102724962B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
CN201080060547.0A 2009-11-09 2010-11-01 包衣药物球状体及其用于消除或减少病症比如呕吐和腹泻的用途 Active CN102724962B (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201710247663.7A CN107441058A (zh) 2009-11-09 2010-11-01 包衣药物球状体及消除或减少病症如呕吐和腹泻的用途
CN201610509189.6A CN106074445B (zh) 2009-11-09 2010-11-01 包衣药物球状体及其制备消除或减少病症的药物的用途
CN201710247590.1A CN107308130B (zh) 2009-11-09 2010-11-01 包衣药物球状体及消除或减少病症如呕吐和腹泻的用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25938709P 2009-11-09 2009-11-09
US61/259,387 2009-11-09
PCT/US2010/054934 WO2011056741A2 (en) 2009-11-09 2010-11-01 Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN201610509189.6A Division CN106074445B (zh) 2009-11-09 2010-11-01 包衣药物球状体及其制备消除或减少病症的药物的用途
CN201710247590.1A Division CN107308130B (zh) 2009-11-09 2010-11-01 包衣药物球状体及消除或减少病症如呕吐和腹泻的用途
CN201710247663.7A Division CN107441058A (zh) 2009-11-09 2010-11-01 包衣药物球状体及消除或减少病症如呕吐和腹泻的用途

Publications (2)

Publication Number Publication Date
CN102724962A CN102724962A (zh) 2012-10-10
CN102724962B true CN102724962B (zh) 2017-05-17

Family

ID=43828063

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201080060547.0A Active CN102724962B (zh) 2009-11-09 2010-11-01 包衣药物球状体及其用于消除或减少病症比如呕吐和腹泻的用途
CN201710247590.1A Active CN107308130B (zh) 2009-11-09 2010-11-01 包衣药物球状体及消除或减少病症如呕吐和腹泻的用途
CN201610509189.6A Active CN106074445B (zh) 2009-11-09 2010-11-01 包衣药物球状体及其制备消除或减少病症的药物的用途
CN201710247663.7A Pending CN107441058A (zh) 2009-11-09 2010-11-01 包衣药物球状体及消除或减少病症如呕吐和腹泻的用途

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201710247590.1A Active CN107308130B (zh) 2009-11-09 2010-11-01 包衣药物球状体及消除或减少病症如呕吐和腹泻的用途
CN201610509189.6A Active CN106074445B (zh) 2009-11-09 2010-11-01 包衣药物球状体及其制备消除或减少病症的药物的用途
CN201710247663.7A Pending CN107441058A (zh) 2009-11-09 2010-11-01 包衣药物球状体及消除或减少病症如呕吐和腹泻的用途

Country Status (11)

Country Link
US (2) US8524281B2 (enExample)
EP (1) EP2498751B1 (enExample)
JP (3) JP5866116B2 (enExample)
CN (4) CN102724962B (enExample)
AR (1) AR078951A1 (enExample)
AU (1) AU2010315362B2 (enExample)
CA (1) CA2780332C (enExample)
ES (1) ES2729677T3 (enExample)
NZ (1) NZ599762A (enExample)
TW (1) TWI429437B (enExample)
WO (1) WO2011056741A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108421044A (zh) 2005-02-03 2018-08-21 综合医院公司 治疗吉非替尼耐药性癌症的方法
BRPI0618042A2 (pt) 2005-11-04 2011-08-16 Wyeth Corp usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN102641270A (zh) 2008-06-17 2012-08-22 惠氏有限责任公司 含有hki-272和长春瑞滨的抗肿瘤组合
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
IL264349B2 (en) 2009-04-06 2024-01-01 Wyeth Llc Regimen comprising neratinib for the treatment of cancer
NZ599762A (en) 2009-11-09 2014-07-25 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
CN102675287A (zh) * 2011-03-11 2012-09-19 江苏恒瑞医药股份有限公司 (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用
US9301957B2 (en) * 2011-11-14 2016-04-05 Novartis Ag Immediate release 4-methyl-3-4[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-YL)-3-(trifluoromethyl)phenyl] benzamide formulation
WO2025213381A1 (en) * 2024-04-10 2025-10-16 Hangzhou Jitai Pharmaceutical Technology Co., Ltd Neratinib-cyclodextrin composition and method for preparing same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1886119A (zh) * 2003-10-01 2006-12-27 惠氏公司 泮托拉唑多颗粒制剂
EP1854463A1 (en) * 2005-03-03 2007-11-14 Takeda Pharmaceutical Company Limited Release-control composition
CN101247791A (zh) * 2005-07-15 2008-08-20 惠氏公司 O-去甲基文拉法辛琥珀酸盐的高生物可利用的口服缓释剂型
CN101431986A (zh) * 2006-05-05 2009-05-13 惠氏公司 固体剂型调配物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54119021A (en) * 1978-03-06 1979-09-14 Nippon Kayaku Co Ltd Carcinostatic agent
JPH0436237A (ja) * 1990-06-01 1992-02-06 Taiho Yakuhin Kogyo Kk 抗腫瘍性複合製剤
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
IL161921A0 (en) 2001-11-27 2005-11-20 Wyeth Corp 3-Cyanoquinolines as inhibitors of egf-r and her2 kinases
US20040122048A1 (en) * 2002-10-11 2004-06-24 Wyeth Holdings Corporation Stabilized pharmaceutical composition containing basic excipients
CL2004000016A1 (es) 2003-01-21 2005-04-15 Wyeth Corp Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
US20050025825A1 (en) * 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
AU2004266572A1 (en) 2003-08-01 2005-03-03 Wyeth Holdings Corporation Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
US20050142192A1 (en) 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
EP3611273A1 (en) 2004-03-31 2020-02-19 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
DE602006012972D1 (de) 2005-04-28 2010-04-29 Wyeth Corp Mikronisierte tanaproget zusammensetzungen und verfahren zu ihrer herstellung
CN101180269A (zh) * 2005-05-25 2008-05-14 惠氏公司 制备3-氰基-喹啉的方法和由其制得的中间体
BRPI0618042A2 (pt) 2005-11-04 2011-08-16 Wyeth Corp usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
CN101300029A (zh) * 2005-11-04 2008-11-05 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
PL1948180T3 (pl) * 2005-11-11 2013-09-30 Boehringer Ingelheim Int Terapia skojarzona raka polegająca na podawaniu inhibitorów EGFR/HER2
CN101340895A (zh) * 2005-12-22 2009-01-07 惠氏公司 包含替加环素的口服制剂
KR20090104862A (ko) 2007-01-12 2009-10-06 와이어쓰 정제내 정제 조성물
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009061349A1 (en) 2007-11-05 2009-05-14 Puretech Ventures Methods, kits, and compositions for administering pharmaceutical compounds
CN101185633A (zh) * 2007-12-14 2008-05-28 山东蓝金生物工程有限公司 一种治疗实体肿瘤的尼拉替尼缓释植入剂
CA2711558C (en) * 2008-01-04 2016-12-13 Intellikine, Inc. Phosphatidyl inositol-3 kinase inhibiting compounds
US20090246198A1 (en) * 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
TWI519322B (zh) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
CN102641270A (zh) 2008-06-17 2012-08-22 惠氏有限责任公司 含有hki-272和长春瑞滨的抗肿瘤组合
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
WO2010048477A2 (en) 2008-10-24 2010-04-29 Wyeth Llc Improved process for preparation of coupled products from 4-amino-3-cyanoquinolines using stabilized intermediates
IL264349B2 (en) 2009-04-06 2024-01-01 Wyeth Llc Regimen comprising neratinib for the treatment of cancer
RU2011152105A (ru) 2009-07-02 2013-08-10 УАЙТ ЭлЭлСи Составы таблеток 3-цианохинолина и их применение
US20120135952A1 (en) 2009-07-17 2012-05-31 Hanall Biopharma Co., Ltd. Butyric acid salt of n,n-dimethyl imidocarbon imidic diamide, method of preparing same, and pharmaceutical compositions and combinations containing same
WO2011008053A2 (ko) 2009-07-17 2011-01-20 한올바이오파마주식회사 Ｎ,ｎ-디메틸 이미도디카르본이미딕 디아미드의 프로피온산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
KR20110021691A (ko) 2009-08-25 2011-03-04 한올바이오파마주식회사 메트포르민 메탄설폰산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
KR101211227B1 (ko) 2009-08-25 2012-12-11 한올바이오파마주식회사 메트포르민 아스코르브산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
KR101190953B1 (ko) 2009-08-25 2012-10-12 한올바이오파마주식회사 메트포르민 타우린염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
NZ599762A (en) 2009-11-09 2014-07-25 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
FI4066821T3 (fi) 2009-11-09 2025-05-13 Wyeth Llc Neratinibimaleaatin tablettiformulaatioita
EP3575413A1 (en) 2009-12-11 2019-12-04 Wyeth LLC Phosphatidylinositol-3-kinase pathway biomarkers
CA2787048C (en) 2010-01-13 2021-06-22 Wyeth Llc A cut-point in pten protein expression that accurately identifies tumors and is predictive of drug response to a pan-erbb inhibitor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1886119A (zh) * 2003-10-01 2006-12-27 惠氏公司 泮托拉唑多颗粒制剂
EP1854463A1 (en) * 2005-03-03 2007-11-14 Takeda Pharmaceutical Company Limited Release-control composition
CN101247791A (zh) * 2005-07-15 2008-08-20 惠氏公司 O-去甲基文拉法辛琥珀酸盐的高生物可利用的口服缓释剂型
CN101431986A (zh) * 2006-05-05 2009-05-13 惠氏公司 固体剂型调配物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors;Kwok-K.Wong et al.;《Clinical Cancer Research》;20090401;第15卷(第7期);第2552-2558页 *

Also Published As

Publication number Publication date
NZ599762A (en) 2014-07-25
AU2010315362A1 (en) 2012-05-24
EP2498751B1 (en) 2019-04-03
US9211264B2 (en) 2015-12-15
ES2729677T3 (es) 2019-11-05
WO2011056741A3 (en) 2011-06-30
JP2015078240A (ja) 2015-04-23
CA2780332C (en) 2018-01-30
US20140004203A1 (en) 2014-01-02
CN107308130A (zh) 2017-11-03
CN102724962A (zh) 2012-10-10
CN106074445A (zh) 2016-11-09
TWI429437B (zh) 2014-03-11
JP2016094478A (ja) 2016-05-26
CN107308130B (zh) 2021-06-15
EP2498751A2 (en) 2012-09-19
CA2780332A1 (en) 2011-05-12
CN107441058A (zh) 2017-12-08
JP2011098965A (ja) 2011-05-19
CN106074445B (zh) 2018-12-21
WO2011056741A2 (en) 2011-05-12
TW201138775A (en) 2011-11-16
US8524281B2 (en) 2013-09-03
AR078951A1 (es) 2011-12-14
US20110165257A1 (en) 2011-07-07
JP5982020B2 (ja) 2016-08-31
JP5866116B2 (ja) 2016-02-17
AU2010315362B2 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
CN107308130B (zh) 包衣药物球状体及消除或减少病症如呕吐和腹泻的用途
CN103893140B (zh) 来那替尼马来酸盐的片剂制剂
US6726927B2 (en) Preparation of enteric pharmaceutical dosage forms for omerprazole and lansoprazole
CN1886119B (zh) 泮托拉唑多颗粒制剂
RU2504362C2 (ru) Системы доставки лекарственных веществ, включающие в себя слабоосновные лекарственные вещества и органические кислоты
KR101190708B1 (ko) 모사프리드 또는 이의 염을 포함하는 서방형 약학 조성물
KR19980702828A (ko) 양성자 펌프 억제제 및 프로키네틱제 함유 경구 제약 제형
KR20140053307A (ko) 맛이 차폐된 약제학적 조성물
CN104010632B (zh) 双层片剂形式的贝那普利和匹莫苯的固定剂量组合
CN108201536A (zh) 一种奥拉帕尼口服缓控释药物组合物及其用途
CN102470109A (zh) 3-氰基喹啉片剂制剂及其应用
TW202313072A (zh) 檸檬酸鐵之兒科調配物
HK1230944B (zh) 包衣藥物球狀體及其製備消除或減少病症的藥物的用途
HK1230944A1 (en) Coated drug spheroids and uses thereof for preparing medicament for eliminating or reducing conditions
HK1175719B (en) Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
HK1175719A (en) Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
WO2026064388A1 (en) Fixed dose combination of flavoxate and alpha-blockers, and formulations and manufacturing processes thereof
CN101102750A (zh) 治疗胃肠道病症的剂型
JP2008530185A (ja) ロサルタンの経口医薬剤形態
HK1086766B (en) Pantoprazole multiparticulate formulations

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20121010

Assignee: Beihai Kangcheng Pharmaceutical Co., Ltd

Assignor: Lion biopharmaceutical company

Contract record no.: X2020990000295

Denomination of invention: Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea

Granted publication date: 20170517

License type: Common License

Record date: 20200611

EE01 Entry into force of recordation of patent licensing contract
EC01 Cancellation of recordation of patent licensing contract

Assignee: Beihai Kangcheng Pharmaceutical Co., Ltd

Assignor: Lion biopharmaceutical company

Contract record no.: X2020990000295

Date of cancellation: 20211015

EC01 Cancellation of recordation of patent licensing contract